552331-15-4 Usage
General Description
1-(5-Bromo-2-fluorophenyl)ethanol is a chemical compound with the molecular formula C8H8BrFO. It is an organic compound that belongs to the class of phenols, which are aromatic organic compounds that have a hydroxyl group attached to one of the carbon atoms in the aromatic ring. This particular compound has a bromine atom and a fluorine atom attached to a phenyl ring, and an ethanol group attached to the phenyl ring. It is used in organic synthesis as a building block for the preparation of various pharmaceuticals, agrochemicals, and other specialty chemicals. Its properties and reactivity make it a versatile compound for use in various chemical reactions and processes.
Check Digit Verification of cas no
The CAS Registry Mumber 552331-15-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,5,2,3,3 and 1 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 552331-15:
(8*5)+(7*5)+(6*2)+(5*3)+(4*3)+(3*1)+(2*1)+(1*5)=124
124 % 10 = 4
So 552331-15-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H8BrFO/c1-5(11)7-4-6(9)2-3-8(7)10/h2-5,11H,1H3
552331-15-4Relevant articles and documents
TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS
-
Paragraph 00199, (2020/11/30)
Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating fibrosis in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating fibrosis
COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS
-
Paragraph 00223, (2020/12/01)
Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.
IRE1 SMALL MOLECULE INHIBITORS
-
Paragraph 00259, (2019/05/30)
Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
